Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 2:2:48.
doi: 10.3389/fcell.2014.00048. eCollection 2014.

Intractable diseases treated with intra-bone marrow-bone marrow transplantation

Ming Li  1 , Kuquan Guo  2 , Susumu Ikehara  1
Affiliations
Review

Intractable diseases treated with intra-bone marrow-bone marrow transplantation

Ming Li et al. Front Cell Dev Biol. .

Abstract

Bone marrow transplantation (BMT) is used to treat hematological disorders, autoimmune diseases (ADs) and lymphoid cancers. Intra bone marrow-BMT (IBM-BMT) has been proven to be a powerful strategy for allogeneic BMT due to the rapid hematopoietic recovery and the complete restoration of T cell functions. IBM-BMT not only replaces hematopoietic stem cells (HSCs) but also mesenchymal stromal cells (MSCs). MSCs are multi-potent stem cells that can be isolated from bone marrow (BM), umbilical cord blood (UCB), and adipose tissue. MSCs play an important role in the support of hematopoiesis, and modify and influence the innate and adaptive immune systems. MSCs also differentiate into mesodermal, endodermal and ectodermal lineage cells to repair tissues. This review aims to summarize the functions of BM-derived-MSCs, and the treatment of intractable diseases such as rheumatoid arthritis (RA) and malignant tumors with IBM-BMT.

Keywords: autoimmune diseases; intra-bone marrow-bone marrow transplantation; malignant tumors; mesenchymal stem cell; rheumatoid arthritis.

PubMed Disclaimer

References

    1. Abraham N. G., Li M., Vanella L., Peterson S. J., Ikehara S., Asprinio D. (2008). Bone marrow stem cell transplant into intra-bone cavity prevents type 2 diabetes: role of heme oxygenase-adiponectin. J. Autoimmun. 30, 128–135. 10.1016/j.jaut.2007.12.005 - DOI - PubMed
    1. Aggarwal S., Pittenger M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815–1822. 10.1182/blood-2004-04-1559 - DOI - PubMed
    1. Aldinucci A., Rizzetto L., Pieri L., Nosi D., Romagnoli P., Biagioli T., et al. . (2010). Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J. Immunol. 185, 5102–5110. 10.4049/jimmunol.1001332 - DOI - PubMed
    1. Anderson M. S., Bluestone J. A. (2005). The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485. 10.1146/annurev.immunol.23.021704.115643 - DOI - PubMed
    1. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. . (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214–2219. 10.1182/blood-2004-07-2921 - DOI - PubMed

LinkOut - more resources